LabMedica

Download Mobile App
Recent News Expo
Medica 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

CRISPR-Based Test Detects SARS-CoV-2 from Respiratory Swab RNA Extracts in 45 Minutes

By LabMedica International staff writers
Posted on 27 Apr 2020
Image: DETECTR™ (Photo courtesy of Mammoth Biosciences)
Image: DETECTR™ (Photo courtesy of Mammoth Biosciences)
A newly-published study of an assay for detecting SARS-CoV-2 from respiratory swab RNA extracts in less than 45 minutes contains the first peer-reviewed data using CRISPR diagnostics for COVID-19, with the largest set of patient samples to-date.

In the study, Mammoth Biosciences (San Francisco, CA, USA) demonstrated how the diagnostic capabilities of CRISPR can be leveraged to offer a faster, lower-cost and visual alternative to traditional quantitative polymerase chain reaction (qRT-PCR) assays for diagnosing SARS-CoV-2. The researchers validated the method using contrived reference samples and clinical samples from US patients, including 36 patients with COVID-19 infection and 42 patients with other viral respiratory infections.

The company’s CRISPR-based diagnostic assay, DETECTR, can deliver results in under 45 minutes as visualized on a lateral flow strip, similar to an at-home pregnancy test. DETECTR does not require a complex laboratory setting; it can be performed with portable heat blocks and readily available, “off-the-shelf” reagents and disposable lateral flow strips. The assay offers similar levels of sensitivity and specificity to qRT-PCR tests, with 95% positive predictive agreement and 100% negative predictive agreement.

“We need faster, more accessible and scalable diagnostics. The point-of-care testing space is ripe for disruption and CRISPR diagnostics have the potential to bring reliable testing to the most vulnerable environments,” said Mammoth’s Chief Technology Officer Janice Chen. “Because CRISPR can be programmed to detect any DNA or RNA sequence, we have been able to reconfigure our DETECTR platform within days to detect the SARS-CoV-2 virus from one of the first confirmed cases in the US, made possible by our collaboration with Dr. Charles Chiu at UCSF.”

Related Links:
Mammoth Biosciences

Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Manual Pipetting Aid
Pipette Controllers macro
Nucleic Acid Purification Instrument
QIAsymphony Connect

Channels

Clinical Chemistry

view channel
Image: Led by Professor Sherry Chan Kit-wa (middle), the HKUMed research team provides the first large-scale Chinese population evidence to support reviewing Hong Kong’s long-term blood-monitoring requirements for clozapine use. (Photo courtesy of HKUMed)

Study Supports Review of Long-Term Blood-Monitoring Guidelines for Clozapine

Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia for which clozapine remains the only antipsychotic specifically approved by the U.S. Food and Drug Administration (FDA).... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more